VASCO is a prospective observational cohort study which aim to describe the presentation, comorbidities, management, outcomes and damage of vasculitis patients, from the analysis of the clinical, biological and immunological data.

Vasculitis is a group of disorders characterized by the inflammation of blood vessels, leading to an alteration of the vascular wall. The classification of vasculitides has evolved considerably over the last few decades.

In 1990, the American College of Rheumatology established a classification of the main systemic vasculitides based on clinical, biological and histological criteria. In 1994, the Chapel Hill nomenclature has been established as the reference classification system of vasculitides and vasculitides were classified according to the size of the affected vessels. The Chapel Hill nomenclature was revised in 2012, thus enabling to integrate new vasculitides and diagnostic tools.

It is proposed here to conduct a non-interventional cohort study of the different forms of vasculitis, as defined in the Chapel Hill nomenclature. By collecting data from a large number of patients followed prospectively, our objective is to describe the clinical patterns of these diseases, the presentation, management, comorbidities and outcomes, and to evaluate their possible association with some immunological, genetic and molecular parameters.

Inclusion Criteria:

• Adult patients (age over 18 years),
• Patients with vasculitis, as defined in the Chapel Hill International Nomenclature as revised in 2012,
• Patients included at an active phase of the disease, either the initial flare or a relapse,
• Patients who have been informed and have signed the consent
• Pregnant and breastfeeding women may be included in the study,
• Affiliated to a social security system (beneficiary or entitled person).

Exclusion Criteria:

• Refusal of consent or inability to obtain consent,
• A patient who is insane or not entitled, for psychiatric reasons or intellectual impairment, to receive information about the protocol and to give informed consent,
• Patient under guardianship / curators
• Patient on state medical assistance (AME)
• Hemoglobin less than 7 g/dl at the time of sampling,
• Hemoglobin level less than 9 g/dl at the time of sampling if the patient has respiratory or cardiovascular disease,
• Patient weighs less than 18 kg.
• Parallel participation in an interventional protocol is permitted.

The VASCO study population includes adult patients (no age upper-limit) with vasculitis as defined in the 2012 revised Chapel Hill International Nomenclature, at an active phase of the disease, either the initial flare or a relapse. Patients will be informed by the study investigator during a visit as part of their medical follow-up.

Undecided